User profiles for J. J. Renger

John J. Renger, Ph.D.

Cerevel Therapeutics
Verified email at cerevel.com
Cited by 9795

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology

AL Gotter, AL Webber, PJ Coleman, JJ Renger… - Pharmacological …, 2012 - ASPET
Orexin signaling is essential for normal regulation of arousal and behavioral state control
and represents an attractive target for therapeutics combating insomnia. Alternatively termed …

Discovery and development of orexin receptor antagonists as therapeutics for insomnia

CJ Winrow, JJ Renger - British journal of pharmacology, 2014 - Wiley Online Library
Insomnia persistently affects the quality and quantity of sleep. Currently approved treatments
for insomnia primarily target γ‐aminobutyric acid‐ A ( GABA‐A ) receptor signalling and …

The discovery of suvorexant, the first orexin receptor drug for insomnia

…, WJ Herring, CJ Winrow, JJ Renger - Annual review of …, 2017 - annualreviews.org
Historically, pharmacological therapies have used mechanisms such as γ-aminobutyric acid
A (GABA A ) receptor potentiation to drive sleep through broad suppression of central …

Improved stability of Drosophila larval neuromuscular preparations in haemolymph-like physiological solutions

BA Stewart, HL Atwood, JJ Renger, J Wang… - Journal of Comparative …, 1994 - Springer
Neuromuscular preparations from third instar larvae of Drosophila are not well-maintained in
commonly used physiological solutions: vacuoles form in the muscle fibers, and membrane …

Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl] …

…, KS Koblan, CJ Winrow, JJ Renger… - Journal of medicinal …, 2010 - ACS Publications
Despite increased understanding of the biological basis for sleep control in the brain, few
novel mechanisms for the treatment of insomnia have been identified in recent years. One …

Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist

…, DR Reiss, D Cui, PJ Coleman, JJ Renger - Journal of …, 2011 - Taylor & Francis
Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and
reward circuits. Two receptors respond to orexin signaling, orexin 1 receptor (OX 1 R) and …

Essential thalamic contribution to slow waves of natural sleep

…, G Di Giovanni, VN Uebele, JJ Renger… - Journal of …, 2013 - Soc Neuroscience
Slow waves represent one of the prominent EEG signatures of non-rapid eye movement (non-REM)
sleep and are thought to play an important role in the cellular and network plasticity …

Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells

…, NG Hatcher, J Schachter, JJ Renger… - Journal of …, 2015 - Soc Neuroscience
Neuronal inclusions of hyperphosphorylated and aggregated tau protein are a pathological
hallmark of several neurodegenerative tauopathies, including Alzheimer's disease (AD). The …

Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of ITwindow

…, A Tscherter, AC Errington, JJ Renger… - Journal of …, 2010 - Soc Neuroscience
Although it is well established that low-voltage-activated T-type Ca 2+ channels play a key
role in many neurophysiological functions and pathological states, the lack of selective and …

Presynaptic HCN1 channels regulate CaV3.2 activity and neurotransmission at select cortical synapses

…, R Lujan, I Kadurin, VN Uebele, JJ Renger… - Nature …, 2011 - nature.com
The hyperpolarization-activated cyclic nucleotide–gated (HCN) channels are subthreshold,
voltage-gated ion channels that are highly expressed in hippocampal and cortical pyramidal …